The company lacks meaningful commercial scale, generating only $36,251 in revenue during 2025Q4 while incurring $4.0 million in combined R&D and SG&A expenses.
| Sales/Revenue | 36.25K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 29.27K | 106.21K | 537.4K | 571.14K | 976.98K | 798.45K | 754K | 734.5K | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | -29.27K | -106.21K | -537.4K | -571.14K | -976.98K | -798.45K | -754K | -734.5K | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | 100% | 72.44% | 80.24% | 5.91% | 41.54% | -22.36% | -5.9% | -2.65% | - | - | - | - |
| Operating Expenses | 6.43M | 15.62K | 15.77M | 12.68M | 56.7M | 26.43M | 14.74K | 13.43K | 10.22K | 8.65K | 4.34K | 2.88K | 1.01K |
| OpEx % of Revenue | 17726.42% | - | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 5.5M | 14.72K | 10.74M | 11.99M | 18.38M | 7.29M | 6.06K | 7.45K | 7.69K | 4.13K | 3.33K | 1.87K | 537 |
| SG&A % of Revenue | 15173.44% | - | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 925.48K | 904 | 5.03M | 691.26K | 38.32M | 19.14M | 8.68K | 5.77K | 2.4K | 2.5K | 1.4K | 1.05K | 433 |
| R&D % of Revenue | 2552.98% | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 529.1K | 211.43K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -7.08M | -15.62K | -15.77M | -12.68M | -59.06M | -26.43M | -14.74K | -13.22K | -10.08K | -6.63K | -4.73K | -2.92K | -969 |
| Operating Margin % | -19539.98% | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | -45244.82% | 99.9% | -24.39% | 78.53% | -123.42% | -179181.21% | -11.51% | -31.15% | -52.17% | -40.1% | -62.15% | -200.83% | - |
| EBITDA | -7.08M | 33.33K | -15.74M | -12.65M | -58.51M | -25.87M | -14.11K | -12.42K | -9.33K | -5.89K | -4K | -2.48K | -958 |
| EBITDA Margin % | -19539.98% | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -21355.8% | 100.21% | -24.45% | 78.38% | -126.21% | -183243.76% | -13.57% | -33.19% | -58.34% | -47.44% | -60.95% | -159.2% | - |
| D&A (Non-Cash Add-back) | 0 | 48.95K | 29.27K | 29.27K | 542.25K | 565.35K | 635 | 798 | 754 | 734 | 734 | 434 | 12 |
| EBIT | 0 | -15.62K | -15.77M | -14.61M | -58.53M | -26.83M | -14.74M | -13.43M | -10.22M | -8.65M | -4.34M | -2.3M | -969 |
| Net Interest Income | 0 | 1 | -19.93K | -7.46K | -10.06K | -5.84M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 0 | 1 | 2.53K | 8.41K | 1.17K | 484 | 0 | 102 | 875 | 5.94K | 1.59K | 68 | 0 |
| Interest Expense | -490.83K | 0 | 22.46K | 15.88K | 11.23K | 5.84M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 529.86K | 2 | -24.16K | -1.95M | -1.83M | -6.24M | -433.94K | -311.85K | -1.02M | -7.97M | -1.2M | 551.16K | -45 |
| Pretax Income | -6.55M | -15.62K | -15.79M | -14.63M | -58.54M | -32.67M | -15.18K | -13.53K | -11.1K | -14.59K | -5.93K | -2.95K | -1.01K |
| Pretax Margin % | -18078.34% | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -587 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 19.88% | 0% |
| Net Income | -6.55M | -18.06M | -15.79M | -14.63M | -58.54M | -32.67M | -15.18M | -13.53M | -11.1M | -14.59M | -5.93M | -2.37M | -1.01K |
| Net Margin % | -18078.34% | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 63.71% | -14.34% | -7.97% | 75.01% | -79.17% | -115.26% | -12.15% | -21.96% | 23.95% | -146.06% | -150.73% | -233139.88% | - |
| Net Income (Continuing) | -6.55M | -15.62K | -15.79M | -14.63M | -58.54M | -32.67M | -15.18M | -13.53M | -11.1M | -14.59M | -5.93M | -2.37M | -1.01K |
| Discontinued Operations | 0 | -2.44M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 5.13M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -4.16 | -5.26 | -46.96 | -407.37 | -27544.98 | -48255.29 | -28425.72 | -36815.89 | -43847.52 | -94215.17 | -25480.07 | -10162.18 | -4.36 |
| EPS Growth % | 20.91% | 88.8% | 88.47% | 98.52% | 42.92% | -69.76% | 22.79% | 16.04% | 53.46% | -269.76% | -150.73% | -232977.52% | - |
| EPS (Basic) | -4.16 | -3.88 | -46.96 | -407.37 | -27544.98 | -48255.29 | -28425.72 | -36815.89 | -43847.52 | -94215.17 | -25480.07 | -10162.18 | -4.36 |
| Diluted Shares Outstanding | 1.62M | 3.43M | 336.34K | 35.91K | 2.13K | 677 | 534 | 368 | 253 | 155 | 233 | 233 | 233 |
| Basic Shares Outstanding | 1.62M | 4.65M | 336.34K | 35.91K | 2.13K | 677 | 534 | 368 | 253 | 155 | 233 | 233 | 233 |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - |
Imminent liquidity and dilution risk
As reported in recent financial filings, ENTO generated a nominal $36,251 in revenue during 2025Q4, which remains entirely disconnected from core clinical operations and does not represent a sustainable growth trajectory for a company currently focused on the development of its latiglutenase pipeline assets.
The absence of consistent revenue streams underscores the company's status as a pre-commercial entity reliant on external capital. Investors should interpret this figure as incidental rather than indicative of market penetration or product-market fit.
Based on the company's latest income statement, R&D and SG&A expenses totaled approximately $4.0 million in 2025Q4, reflecting a high-burn cost structure that is typical for clinical-stage biotechs but unsustainable given the current lack of recurring revenue to offset these significant operational outlays.
The concentration of spending in R&D and professional fees suggests that management is prioritizing clinical trial progression over cost containment. This aggressive spending profile warrants close monitoring, as it directly accelerates the depletion of the company's limited cash reserves.
According to historical income statement data, ENTO's net losses are frequently exacerbated by non-operating items and stock-based compensation, with $734,000 in SBC recorded in 2025Q4 alone, which further complicates the assessment of true operational performance for existing shareholders facing significant potential equity dilution.
The volatility in EPS, including anomalous positive net income in 2024Q1, suggests that traditional earnings metrics are poor indicators of underlying business health. Analysts should focus on cash burn and share count expansion rather than reported net income to gauge the company's true financial trajectory.
As indicated by the reported $899,784 in cash reserves, ENTO faces a precarious financial position that may necessitate immediate dilutive financing, a reality that short-sellers likely emphasize when questioning the company's ability to fund the critical Phase 3 trials required for its lead asset's validation.
The disconnect between the capital required for late-stage clinical development and the current cash position suggests a high probability of further equity issuance. Investors should consider whether the potential upside of the latiglutenase program justifies the substantial risk of near-term capital structure impairment.
Quick answers to the most common questions about buying ENTO stock.
For fiscal year 2025, Entero Therapeutics, Inc. (ENTO) reported total revenue of $0.0M.
Entero Therapeutics, Inc. (ENTO) reported a net loss of $6.6M for the fiscal year ending 2025.
Entero Therapeutics, Inc. (ENTO) reported an operating income of $-7.1M, resulting in an operating profit margin of -19540.0%. This margin reflects the operational efficiency of the business before interest and taxes.